The U.S. Food and Drug Administration proposed on April 30, 2026, to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that large-scale compounding facilities are legally permitted to use, finding no clinical need for outsourcing facilities to compound these drugs now that brand-name versions are available without shortage. The proposal, which remains open for public comment through late July, would close the last major regulatory pathway that enabled an industry supplying compounded GLP-1 drugs to roughly one in three Americans who used the medications at the market’s 2024 peak.
Key Takeaways
- The FDA proposed on April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, the regulatory mechanism governing which active ingredients large-scale compounding operations may use.
- At their 2024 peak, compounded versions accounted for approximately 30% of total U.S. GLP-1 supply, with patients paying $150 to $300 per month compared to more than $1,000 for brand-name products.
- The FDA has received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports tied to compounded tirzepatide, with over 100 hospitalizations and at least 10 deaths documented.
- Medicare Part D coverage for GLP-1 drugs expanded in 2025 and 2026, putting brand-name versions within reach for millions of older adults who face specific risks including accelerated muscle loss and reduced bone density.
- The FDA extended the public comment period through late July 2026. If finalized, the rule would apply specifically to 503B outsourcing facilities; smaller 503A patient-specific compounding remains permitted.
What The Proposal Actually Does
The FDA’s April 30 announcement targets the 503B Bulks List, a provision under Section 503B of the Federal Food, Drug, and Cosmetic Act that identifies which bulk drug substances outsourcing facilities may use in compounding. In most cases, these facilities cannot compound drugs using bulk substances unless the ingredient appears on the 503B Bulks List or the compounded drug is on the FDA’s active drug shortage list at the time of compounding, distribution, and dispensing. Semaglutide was placed on the shortage list in 2022 and removed in February 2025. Tirzepatide was added in 2022 and removed in 2024. With both shortages resolved, the shortage-list pathway closed. The FDA’s current proposal would close the remaining bulks-list pathway by finding no clinical need for any of the three substances.
FDA Commissioner Marty Makary framed the decision in terms of patient protection and regulatory integrity. The agency evaluated nominations submitted for all three substances and concluded that FDA-approved products are available, outsourcing facilities cannot lawfully compound using bulk drug substances without a clear clinical need, and the evidence did not support inclusion on the list.
The Safety Record That Drove The Proposal
The FDA’s action rests on a documented safety record that has worsened as compounded GLP-1 products proliferated. The agency received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials. Stanford Medicine clinicians reported in July 2026 that FDA safety data documented over 100 hospitalizations and at least 10 deaths linked to compounded semaglutide, primarily from dosing errors. A 2026 study found that when tirzepatide is compounded with vitamin B12, the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug, raising questions about the therapeutic equivalence of combination formulations that compounders have widely marketed.
Quality control issues extend beyond the pharmacy counter. More than one in five of 48 GLP-1 active pharmaceutical ingredient manufacturing sites the FDA assessed were non-compliant or failed to provide required records. The agency cited one Chinese firm for shipping relabeled semaglutide API from unapproved suppliers and releasing tirzepatide API without validated testing methods. In April 2026, the family of a Texas woman filed a wrongful-death suit alleging a compounded GLP-1 product was contaminated and defectively formulated.
The Access And Affordability Tension
The compounded GLP-1 market did not emerge in a vacuum. It grew because brand-name drugs were both scarce and expensive. FDA-approved semaglutide and tirzepatide carried list prices exceeding $1,000 per month. Compounded alternatives offered the same active ingredients for $150 to $300 per month, delivered directly to consumers through telehealth platforms. At the 2024 peak, compounded versions accounted for roughly 30% of total U.S. GLP-1 supply. That volume represents millions of patients who found the brand-name market inaccessible on price alone.
The coverage picture has shifted since then. Medicare Part D expanded coverage for GLP-1 drugs in 2025 and 2026, first for diabetes management and cardiovascular risk reduction, then for broader indications based on the SELECT trial data showing semaglutide reduced major cardiac events by approximately 20% in people who were overweight but did not have diabetes. Medicaid GLP-1 prescriptions rose from roughly 1 million in 2019 to more than 8 million in 2024, while gross Medicaid spending increased from approximately $1 billion to nearly $9 billion before rebates. However, only 13 state Medicaid programs covered GLP-1 drugs for obesity treatment under fee-for-service Medicaid as of January 2026, leaving significant gaps in access for lower-income patients.
Older Adults Face A Distinct Risk Profile
The expanded Medicare coverage puts GLP-1 drugs within reach of a population that faces specific clinical risks. Older adults on GLP-1 medications experience accelerated muscle mass loss and reduced bone density, both of which compound existing aging-related vulnerabilities. A new report flagged that seniors using these drugs face higher rates of malnutrition, dehydration, and gastrointestinal side effects that lead to treatment discontinuation at rates exceeding those of younger patients. Stanford Medicine experts noted that a large 2026 analysis of more than 9,000 patients found people who stopped semaglutide or tirzepatide regained an average of nearly two pounds per month, with those who lost less than 15% of their body weight regaining the majority of what they lost. For older adults, the cycle of rapid weight loss followed by regain carries particular risks for bone density and functional strength.
What Happens Next
The FDA extended its public comment period through late July 2026 after initially setting a June 29 deadline. The agency will review submitted comments before issuing a final determination. If the rule is finalized as proposed, 503B outsourcing facilities would be permanently barred from compounding semaglutide, tirzepatide, and liraglutide from bulk drug substances unless those drugs return to the FDA’s active shortage list. Smaller 503A compounding pharmacies operating under traditional patient-specific prescriptions would not be directly affected by this particular rule, though separate FDA enforcement actions continue to target individual pharmacies making misleading claims.
The FDA’s proposal to permanently exclude GLP-1 ingredients from large-scale compounding marks the clearest signal yet that the regulatory exception that built a multibillion-dollar compounded weight loss drug industry was always temporary — and that patient safety, not market demand, will determine where the legal lines are drawn.
FAQs
What did the FDA propose on April 30, 2026?
The FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for large-scale compounding facilities to produce these drugs from bulk substances now that brand-name versions are available without shortage.
What are compounded GLP-1 drugs?
Compounded GLP-1 drugs are versions of medications like Ozempic and Wegovy produced by compounding pharmacies rather than the original manufacturers. They typically cost $150 to $300 per month compared to more than $1,000 for brand-name products, but lack FDA approval and have been linked to safety concerns including dosing errors and contamination.
How many people used compounded GLP-1 drugs?
At their 2024 peak, compounded versions accounted for approximately 30% of total U.S. GLP-1 supply. Nearly one in three Americans taking a GLP-1 drug obtained it from a compounding pharmacy during the height of the brand-name shortage.
What safety problems has the FDA documented with compounded GLP-1 drugs?
The FDA received more than 455 adverse event reports for compounded semaglutide and more than 320 for compounded tirzepatide. Safety data documented over 100 hospitalizations and at least 10 deaths, primarily from dosing errors involving multidose vials.
Does Medicare cover GLP-1 drugs?
Medicare Part D coverage expanded in 2025 and 2026 to include GLP-1 drugs for diabetes management and cardiovascular risk reduction. Coverage for obesity treatment without diabetes remains more limited. Medicaid coverage varies by state, with only 13 programs covering GLP-1 drugs for obesity under fee-for-service as of January 2026.
Are compounded GLP-1 drugs safe for older adults?
Older adults face specific risks with any GLP-1 medication, including accelerated muscle mass loss, reduced bone density, and higher rates of dehydration and gastrointestinal side effects. Compounded versions carry additional risks related to dosing accuracy and quality control that compound these age-related vulnerabilities.
Will all compounded GLP-1 drugs become illegal if the rule is finalized?
No. The proposed rule specifically targets 503B outsourcing facilities that produce compounded drugs at industrial scale. Smaller 503A compounding pharmacies that fill individual patient-specific prescriptions under a doctor’s order would not be directly affected by this particular rule, though they remain subject to other FDA regulations.
When will the FDA make a final decision?
The FDA extended its public comment period through late July 2026. After reviewing comments, the agency will issue a final determination. The timeline for finalization has not been specified, but the rulemaking process typically takes several months after the comment period closes.
